About: Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission
Creator	Fukushima, Takuya Hanashiro, Taeko Nakachi, Sawako Nishi, Yukiko Tamaki, Keita Karube, Kennosuke Kitamura, Sakiko Miyagi, Riko Tomori, Shouhei Uchibori, Sachie Kaori Karimata, • Kazuho Morichika, • Masayo Ohama, • Masuzaki, • Miyagi, • Morishima, • Shimabukuro, • Tedokon, • Tomoyose, • Yamanoha, •
Source	PMC
abstract	Outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with adult T cell leukemia/lymphoma (ATL) are not satisfactory, particularly in patients in non-complete remission at transplantation (Pt-non-CR). We conducted a regional retrospective study in the ATL endemic area of Okinawa, Japan. Of 62 ATL patients, 21 received allo-HSCT in CR and 41 in non-CR. The 3-year overall survival (3yOS) rate and median survival time for the whole cohort was 25.6% and 7.7 months, respectively. The 3yOS of Pt-non-CR was significantly lower than that of patients in CR (Pt-CR) (16.8% vs. 43.6%, P = 0.005). Transplant-related mortality (TRM) was significantly higher in Pt-non-CR than in Pt-CR (46.3% vs. 15.7%, P = 0.025), while there was no significant difference in disease-associated mortality (DAM) between Pt-non-CR and Pt-CR. Multivariable analysis for Pt-non-CR revealed that poor performance status (poor-PS) and higher sIL-2R level (high sIL-2R) adversely affected OS. Poor-PS was associated with higher TRM, but not with higher DAM in Pt-non-CR. High sIL-2R did not affect TRM or DAM in Pt-non-CR. Overall, high TRM rates rather than DAM contribute to the poor outcomes of Pt-non-CR, suggesting that not only disease control but also management of transplant-related complications is required for allo-HSCT in ATL patients.
has issue date	2019-09-18(xsd:dateTime)
bibo:doi	10.1038/s41409-019-0669-z
bibo:pmid	31534195
has license	no-cc
sha1sum (hex)	8eb4f69bf719bb209575132a945a6899ebaa0fd1
schema:url	https://doi.org/10.1038/s41409-019-0669-z
resource representing a document's title	Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission
has PubMed Central identifier	PMC7091703
has PubMed identifier	31534195
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:8eb4f69bf719bb209575132a945a6899ebaa0fd1#body_text
is schema:about of	named entity 'TRM' named entity 'transplantation' named entity 'endemic' named entity 'area' named entity 'TRM' named entity 'level' named entity 'high' named entity 'patients' named entity 'non-complete' named entity 'transplantation' named entity 'HIGH' named entity 'OVERALL' named entity 'PATIENTS' named entity 'RELATED' named entity 'non-complete' named entity 'ATL' named entity 'The' named entity 'conducted' named entity 'ATL' named entity 'high' named entity 'TRM' named entity 'ATL' named entity 'The' named entity 'patients' named entity 'impediments' named entity 'disease control' named entity 'sIL-2R' named entity 'allogeneic hematopoietic stem cell transplantation' named entity 'HSCT' named entity 'HSCT' named entity 'significant difference' named entity 'allogeneic hematopoietic stem cell transplantation' named entity 'ECOG' named entity 'Okinawa' named entity 'chemotherapy' named entity '21%' named entity 'genetic backgrounds' named entity 'regression model' named entity 'myeloablative' named entity 'retrospective study' named entity 'clinical outcomes' named entity 'Chemotherapy regimens' named entity 'chemotherapy' named entity 'immunotherapy' named entity 'sIL-2R' named entity 'Adult T-cell leukemia/lymphoma' named entity 'infection' named entity 'Okinawa' named entity 'chemotherapy' named entity 'sIL-2R' named entity 'HSCT' named entity 'toxicity' named entity 'survival rates' named entity 'HSCT' named entity 'sIL-2R' named entity '1.26' named entity 'retrospective studies' named entity 'University of the Ryukyus' named entity 'graphical user interface' named entity 'lymphocytes' named entity 'relapse' named entity 'HSCT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software